Completed PHASE3 INTERVENTIONAL 3-arm NCT00568295

A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee

A Four-Week Comparative Study Evaluating Acetaminophen Extended Release (3900 mg/Day) and Rofecoxib (12.5 mg/Day and 25 mg/Day)in the Treatment of Osteoarthritis of the Knee

Sponsor: Johnson & Johnson Consumer and Personal Products Worldwide

Conditions Osteoarthritis of the Knee

Interventions Rofecoxib acetaminophen

Updated 6 times since 2017 Last updated: Aug 19, 2011 Started: Oct 31, 1999 Primary completion: Oct 31, 2000 Completion: Oct 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00568295, this PHASE3 trial focuses on Osteoarthritis of the Knee and remains completed. Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide, it has been updated 6 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Consumer and Personal Products Worldwide

Data source: Johnson & Johnson Consumer and Personal Products Worldwide

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.